EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Isorhamnetin as a promising agent for reducing diabetes-induced cardiac damage: insights into antioxidant and enzyme regulatory mechanisms

Esam Qnais, Abdelrahim Alqudah, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Badriyah S Alotaibi, Alaa A A Aljabali, Taher Hatahet

Molecular Biology Reports · 2025

DOI: 10.1007/s11033-025-10941-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Esam Qnais und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan. Hauptthemen laut MEDLINE: Quercetin, Diabetes Mellitus, Experimental, Antioxidants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Hashemite University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study assessed the protective effect of Isorhamnetin in diabetic rats induced by streptozotocin (STZ).

Methods

Male Wistar rats were randomly divided into five groups. Normal control, Diabetic control, Low dose of Isorhamnetin – 50 mg/kg, High dose of Isorhamnetin – 150 mg/kg, and Metformin – 200 mg/kg. Diabetes was induced by a single intraperitoneal injection of STZ and treatment was given orally for a period of 21 days. The parameters that were observed in this study were oxidative markers, ATPase and phosphatase activities, p53 and VCAM-1gene expression, myocardial injury markers and histopathology.

Result

Diabetic rats increased the level of MDA, decreased antioxidant enzyme catalase, SOD, GPx, and GST activity, decreased ATPase activities of Na+/ K+-ATPase, Ca2+/Mg2+- ATPase, and Mg2+-ATPase, increased the expression of p53 and VCAM-1 gene compared to normal control. Low and High dose of Isorhamnetin significantly decreased the MDA level, increased the antioxidant enzyme activity, ATPase, and Na+/K+-ATPase activity compared to diabetic rats and this activity was similar to metformin. Isorhamntenin decreased the p53 and VCAM gene concisely to the diabetic group, increased AST and ALTand reduced the CK-MB and cardiac troponins. Histopathological study showed that reduced the muscle fiber degeneration and congestion pattern of heart congestion.

Conclusion

Isorhamnetin plays a cardioprotective effect in diabetic rats by reducing oxidative stress, increased antioxidant defense, restored and enzyme activity of ATPase and reduced inflammation and apoptosis. Hence, Isorhamnetin can be used as a promising multi-target drug for diabetes-induced cardiac and injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinDiabetes Mellitus, ExperimentalAntioxidantsAnimalsMaleRats, WistarRatsOxidative StressMyocardiumStreptozocinMetforminAdenosine Triphosphatases

Stichwörter der Autor:innen

CardioprotectionDiabetes mellitusIsorhamnetinOxidative stressSTZ-induced diabetic rats

Substanzen

QuercetinAntioxidants3-methylquercetinStreptozocinMetforminAdenosine Triphosphatases

Autor:innen und Institutionen

  • Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid, 21163, Jordan.
  • North Wales Medical School, Bangor University, Brigantia Building, Penrallt Road, Bangor, Gwynedd, LL57 2AS, Wales, UK. t.hatahet@bangor.ac.uk.

Förderung

  • The Hashemite University

Zitieren

APA

Qnais, E., Alqudah, A., Gammoh, O., Bseiso, Y., Wedyan, M., Alotaibi, B. S., Aljabali, A. A. A., & Hatahet, T. (2025). Isorhamnetin as a promising agent for reducing diabetes-induced cardiac damage: insights into antioxidant and enzyme regulatory mechanisms. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10941-1

Vancouver

Qnais E, Alqudah A, Gammoh O, Bseiso Y, Wedyan M, Alotaibi BS, et al. Isorhamnetin as a promising agent for reducing diabetes-induced cardiac damage: insights into antioxidant and enzyme regulatory mechanisms. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10941-1

BibTeX
@article{Qnais2025,
  author = {Qnais, Esam and Alqudah, Abdelrahim and Gammoh, Omar and Bseiso, Yousra and Wedyan, Mohammed and Alotaibi, Badriyah S and Aljabali, Alaa A A and Hatahet, Taher},
  title = {Isorhamnetin as a promising agent for reducing diabetes-induced cardiac damage: insights into antioxidant and enzyme regulatory mechanisms},
  journal = {Molecular Biology Reports},
  year = {2025},
  doi = {10.1007/s11033-025-10941-1}
}
Kostenlos starten →